Approval from World Health Organization (WHO) Prequalification (WHO PQ) for Amodiaquine Hydrochloride USP

Regulatory Product ApprovalExport Order Hard CurrencyBusiness Updates View source PDF Explain this filing

ANUHPHR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+6.6%Reaction day

₹80.55

prior close

₹81.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%+6.6% vs market

Pharmaceuticals peers, median of 163sector-0.1%+6.7% vs sector

On the reaction day the stock moved 6.6 pts more than Nifty Microcap 250 and 6.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.6

10m

+3.3

15m

+2.2

30m

+1.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+6.6-0.1+6.6-0.1+6.7

Next day

+3.0+1.5+1.5+1.5+1.5

+3.5+3.1+0.3+2.4+1.1

+4.2+3.0+1.2+2.9+1.4

+3.0+1.6+1.5+2.8+0.3

-0.6-1.6+1.0+0.4-0.9

-3.2-0.6-2.5+1.3-4.4

15d

-5.0+2.2-7.2+3.0-8.1

-6.3+2.6-8.8+1.8-8.1

+0.1+8.9-8.8+5.9-5.8

-1.3+11.4-12.7+7.6-8.9

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 163Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Anuh Pharma Ltd has received WHO Prequalification approval for its Amodiaquine Hydrochloride USP, an anti-malarial Active Pharmaceutical Ingredient. Amodiaquine Hydrochloride is an essential WHO-listed medicine used in combination therapies for treating uncomplicated Plasmodium falciparum malaria. The prequalification qualifies the company as a supplier for WHO-procured and donor-funded international programmes. This strengthens Anuh Pharma's positioning as a preferred API supplier for global anti-malarial initiatives.

Likely market impact

WHO prequalification opens access to large-scale international procurement channels, which could drive meaningful export revenue growth for the company going forward.